Key result
ACE inhibitors are effective in reducing cardiovascular mortality and morbidity in patients with heart failure, myocardial infarction, diabetes, and renal dysfunction.
Why the study?
Do ACE inhibitors reduce mortality and morbidity from cardiovascular events in patients with vascular disease without left ventricular dysfunction?
Do ACE inhibitors reduce mortality and morbidity from cardiovascular events in patients with vascular disease without left ventricular dysfunction?
Answers are grounded in this paper and cite their sources.
This editorial discusses the role and efficacy of ACE inhibitors in patients with vascular disease but preserved left ventricular function, likely contextualizing the results of the PEACE trial.
Angiotensin-converting–enzyme (ACE) inhibitors are effective in reducing mortality and morbidity from cardiovascular events among patients who have chronic heart failure due to left ventricular systolic dysfunction and in those who have acute myocardial infarction with or without left ventricular systolic dysfunction. ACE inhibitors are also effective in reducing mortality and morbidity from cardiovascular events in high-risk patients with diabetes mellitus as well as those with renal dysfunction. In addition, ACE inhibitors are effective antihypertensive agents, although current data suggest that they are not more effective in reducing mortality and morbidity from cardiovascular events than other classes of antihypertensive agents with . . .
No takes yet. Share an insight, caveat, or question.
Bertram Pitt (2004) conducted an editorial in Vascular Disease without Left Ventricular Dysfunction. ACE Inhibitors vs. Other classes of antihypertensive agents was evaluated. ACE inhibitors are effective in reducing cardiovascular mortality and morbidity in patients with heart failure, myocardial infarction, diabetes, and renal dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: